GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q1 FY26 results · Apr–Jun 2025
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹805.17 crore (down 1.2% from Q1 FY25) and net profit of ₹205.01 crore (up 12.4% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 805.17 | 814.65 | −1.2% | 974.37 | −17.4% |
| Other income | 43.72 | 35.64 | +22.7% | 40.68 | +7.5% |
| Total income | 848.89 | 850.29 | −0.2% | 1,015.05 | −16.4% |
| Profit before tax | 278.98 | 249.40 | +11.9% | 358.57 | −22.2% |
| Net profit for the period | 205.01 | 182.33 | +12.4% | 262.87 | −22.0% |
| EPS, basic (₹) | 12.10 | 10.76 | +12.5% | 15.52 | −22.0% |
| Net margin (%) | 25.5 | 22.4 | 27.0 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 804.83 | 811.00 | −0.8% | 966.08 | −16.7% |
| Other income | 43.76 | 35.85 | +22.1% | 39.46 | +10.9% |
| Total income | 848.59 | 846.85 | +0.2% | 1,005.54 | −15.6% |
| Profit before tax | 278.57 | 248.49 | +12.1% | 354.90 | −21.5% |
| Net profit for the period | 204.70 | 181.65 | +12.7% | 260.14 | −21.3% |
| EPS, basic (₹) | 12.08 | 10.72 | +12.7% | 15.35 | −21.3% |
| Net margin (%) | 25.4 | 22.4 | 26.9 |
Consolidated
- Filed with BSE
- 01 Aug 2025, 15:31 IST
- Board meeting
- 01 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 01 Aug 2025, 15:31 IST
- Board meeting
- 01 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE